A noninvasive measure of heart and blood vessel function called the TAPSE/sPAP ratio can help doctors objectively assess the severity of day-to-day symptoms in people with pulmonary arterial hypertension (PAH), according to a new study. Researchers found that lower ratio values closely mirror greater physical limitations in patients, providing…
News
A measurement taken by heart MRI was linked to several invasive measures used to assess pulmonary hypertension (PH), a new study shows. The measurement, known as T2RV/LV, “represents a highly promising non-invasive biomarker for risk stratification, disease monitoring, and assessment of treatment response in PH,” the researchers wrote. They…
Two blood-based biomarkers — GDF-15 and NT-proBNP — most accurately distinguished adults with pulmonary hypertension (PH) from healthy individuals in a study that compared five biomarkers. The retrospective study, conducted at Beijing Anzhen Hospital in China, evaluated traditional and newer biomarkers across the four main clinical subtypes of…
Adults with pulmonary arterial hypertension (PAH) taking Remodulin (treprostinil) or Veletri (epoprostenol) safely switched to Uptravi (selexipag) during carefully monitored hospital stays using a rapid dose-titration plan, a new study reports. The findings may help guide clinicians who are transitioning appropriate PAH patients from infusion therapy…
A measure derived from heart and lung imaging data can predict the long-term risk of death for people with newly diagnosed pulmonary arterial hypertension (PAH), a study found. The measure, called FAC/PASP, was better at predicting long-term death rates than a more established measure, TAPSE/PASP, the study showed. Both measures are…
Chronic kidney disease (CKD) is common among people newly diagnosed with pulmonary hypertension (PH), and patients face an increased risk of developing CKD — marked by worsening kidney function over time — as the condition progresses, according to a new study. The researchers found that certain blood flow measures,…
People with severe pulmonary arterial hypertension (PAH) who respond well to early treatment with prostacyclin infusions may be able to reduce or stop the treatment, a study suggested. In a long-term analysis of 101 patients, about one in five achieved enough improvement in heart and lung blood flow measurements…
In China, Volibris (ambrisentan, sold as Letairis and generics in the U.S.) may have advantages over similar medications for pulmonary arterial hypertension (PAH) when considering factors including safety, efficacy, and economic value. That’s according to a study in which a team of experts developed a multi-criteria decision analysis…
Restoring the levels of BMP3, a naturally occurring protein involved in cell communication that regulates pulmonary blood vessels, reversed key features of pulmonary arterial hypertension (PAH) in preclinical models, a study found. Compared with people without PAH, levels of BMP3 were lower in lung tissue, smooth muscle cells that…
A novel score calculated based on markers of liver and heart health may help to predict the risk of future clinical worsening in people with pulmonary arterial hypertension (PAH), according to a new study. “This study utilized routine [tests] to estimate [blood flow] parameters and established a novel hepatic-cardiac…
The U.S. Food and Drug Administration (FDA) has cleared a noninvasive add-on feature for a test that detects heart patterns in people with pulmonary hypertension (PH). The new tool in the Corvista-PH test estimates the likelihood of elevated pulmonary capillary wedge pressure (PCWP), a key marker of heart failure. The…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IKT-001, an experimental formulation of imatinib that Inhibikase Therapeutics is developing to treat pulmonary arterial hypertension (PAH). The FDA gives orphan drug designation to investigational medications that aim to treat rare diseases, defined as conditions…
